Engineering therapeutic antibodies targeting G-protein–coupled receptors
نویسندگان
چکیده
منابع مشابه
Engineering therapeutic antibodies for improved function.
The binding sites on human IgG1 for human Fc gamma receptor (Fc gamma R) I, Fc gamma RIIa, Fc gamma RIIb, Fc gamma RIIIa and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding to all Fc gamma Rs, while Fc gamma RII and Fc gamma RIII utilize distinct sites outside this common set. In addition to residues which abrogated binding to the Fc gamma R, several position...
متن کاملCancer therapeutic antibodies come of age: targeting minimal residual disease.
Ten years after the first clinical application of Rituximab, an anti-CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential of antibody-based therapy is far from exhaustion. The recent application of Trastuzumab, an antibo...
متن کاملTargeting MICA with therapeutic antibodies for the treatment of cancer
MICA and MICB, along with ULPBs, are ligands for the activating receptor NKG2D expressed on NK cells and subsets of T cells in Human. NKG2D ligands are induced by cellular stress and pathogen infections. Their expression is tightly regulated by complex mechanisms both at the mRNA and protein levels. In the case of MICA and MICB, more than 65 and 30 alleles respectively were described with diffe...
متن کاملTherapeutic targeting in nanomedicine: the future lies in recombinant antibodies.
The unique chemical and functional properties of nanoparticles can be harnessed for the delivery of large quantities of various therapeutic biomolecules. Active targeting of nanoparticles by conjugating ligands that bind to target cells strongly facilitates accumulation, internalization into target cells and longer retention at the target site, with consequent enhanced therapeutic effects. Reco...
متن کاملEngineering Antibodies for Improved Targeting of Solid Tumors
Monoclonal antibodies have emerged as an important class of cancer therapeutics due to their ability to specifically bind tumor-expressed antigens. Unfortunately, attempts to treat solid tumors with these drugs are often limited by an inability of the antibodies to fully penetrate the tumor tissue, leaving large regions of untargeted and viable cells. The goal of this thesis is to understand th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental & Molecular Medicine
سال: 2016
ISSN: 2092-6413
DOI: 10.1038/emm.2015.105